Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism.
Consumption of a naturally occurring polyphenol, resveratrol, in particular through drinking moderate amounts of red wine, has been suggested to be beneficial to health. A plethora of in vitro studies published demonstrate various anti-inflammatory actions of resveratrol. The aim of this research was to determine whether any of these anti-inflammatory effects translate in vivo in a rodent model of LPS induced airway inflammation. Resveratrol reduced lung tissue neutrophilia to a similar magnitude as that achieved by treatment with budesonide. This was associated with a reduction in pro-inflammatory cytokines and prostanoid levels. Interestingly, the reduction did not appear to be due to an impact on NF-kappaB activation or the expression of the respective genes as suggested by various in vitro publications. These results suggest that resveratrol may possess anti-inflammatory properties via a novel mechanism. Elucidation of this mechanism may lead to potential new therapies for the treatment of chronic inflammation.
Birrell
M A
MA
Respiratory Pharmacology, National Heart and Lung Institute, Imperial College London, London, UK.
McCluskie
K
K
Wong
S
S
Donnelly
L E
LE
Barnes
P J
PJ
Belvisi
M G
MG
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D019819:Budesonide / Q000008:administration & dosage; D016207:Cytokines / Q000235:genetics; D004247:DNA / Q000378:metabolism; D015232:Dinoprostone / Q000032:analysis; D015870:Gene Expression / Q000187:drug effects; D007249:Inflammation / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000378:metabolism*; D008070:Lipopolysaccharides; D008168:Lung / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D016328:NF-kappa B / Q000502:physiology; D009504:Neutrophils / Q000201:enzymology / Q000473:pathology*; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D010537:Peritoneum / Q000187:drug effects; D009195:Peroxidase / Q000032:analysis; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage*; D014920:Wine / Q000032:analysis*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D016328:NF-kappa B; D013267:Stilbenes; D019819:Budesonide; D004247:DNA; D009195:Peroxidase; D052247:Nitric Oxide Synthase Type II; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; D000077185:Resveratrol